Marion S Subklewe

List of Publications by Year
in descending order

151	10,043	53794 45	46799 89
papers	citations	h-index	g-index

161	161	161	13721
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens. Cancer Immunology, Immunotherapy, 2022, 71, 1705-1718.	4.2	6
2	Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Advances, 2022, 6, 3022-3026.	5.2	13
3	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Haematologica, 2022, 107, 2096-2107.	3.5	17
4	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2022, 6, 3606-3610.	5.2	35
5	GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood, 2022, , .	1.4	51
6	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HemaSphere, 2022, 6, e676.	2.7	35
7	Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research. Critical Reviews in Oncology/Hematology, 2022, 175, 103710.	4.4	9
8	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
9	Integrated multiomic approach for identification of novel immunotherapeutic targets in AML. Biomarker Research, 2022, 10, .	6.8	8
10	Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL. Blood, 2022, 140, 2175-2179.	1.4	20
11	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 2021, 35, 62-74.	7.2	63
12	CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood, 2021, 137, 1037-1049.	1.4	45
13	Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1692-1693.	6.4	2
14	A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 2021, 35, 2243-2257.	7.2	24
15	Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy â€“ a case report. BMC Infectious Diseases, 2021, 21, 121.	2.9	33
16	BiTEs better than CAR T cells. Blood Advances, 2021, 5, 607-612.	5.2	59
17	Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy. Journal of Clinical Oncology, 2021, 39, 419-432.	1.6	34
18	Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection. HemaSphere, 2021, 5, e530.	2.7	14

#	Article	IF	Citations
19	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. HemaSphere, 2021, 5, e533.	2.7	8
20	The PI3Kâ^,-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. Frontiers in Immunology, 2021, 12, 608625.	4.8	8
21	Chimeric Antigen Receptorâ€"Modified T Cells and T Cellâ€"Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	2.3	4
22	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia, 2021, 35, 1843-1863.	7.2	123
23	Chimeric Antigen Receptor T Cells for Glioblastoma. Neurology, 2021, 97, 218-230.	1.1	19
24	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. Cancers, 2021, 13, 2503.	3.7	15
25	Sarcoid-Like Reaction in Non-Hodgkinâ€™s Lymphomaâ€"A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging. Diagnostics, 2021, 11, 1009.	2.6	3
26	CAR-HEMATOTOX: a model for CAR T-cellâ€"related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160
27	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	22.5	80
28	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Science Advances, 2021, 7, .	10.3	56
29	COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. HemaSphere, 2021, 5, e603.	2.7	35
30	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood, 2021, 138, 2655-2669.	1.4	43
31	SIRPÎ±-Î±CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. Journal of Hematology and Oncology, 2021, 14, 155.	17.0	13
32	Future Developments: Immunotherapy in AML. Hematologic Malignancies, 2021, , 339-347.	0.2	0
33	Impaired function and delayed regeneration of dendritic cells in COVID-19. PLoS Pathogens, 2021, 17, e1009742.	4.7	52
34	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
35	Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis. Blood, 2021, 138, 3822-3822.	1.4	2
36	Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE Â® Construct Mediated Cytotoxicity. Blood, 2021, 138, 1172-1172.	1.4	2

#	Article	IF	Citations
37	CHOP but Not Bendamustine Reverses EZH2 Y641 Mutation Induced MHC-I/II Loss in Human Lymphoma Models. Blood, 2021, 138, 2391-2391.	1.4	3
38	Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist. Blood, 2021, 138, 1178-1178.	1.4	1
39	High Bacterial Abundances of Dorea and Pediococcus in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL. Blood, 2021, 138, 2792-2792.	1.4	3
40	The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. Blood, 2021, 138, 3852-3852.	1.4	1
41	ARID1A Controls a Novel Transcriptional Network Regulating FAS in Follicular Lymphoma. Blood, 2021, 138, 3492-3492.	1.4	0
42	Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis. Blood, 2021, 138, 1748-1748.	1.4	0
43	Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology, 2020, 65, 80-90.	9.6	59
44	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia, 2020, 34, 1017-1026.	7.2	33
45	Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting Î±CD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells. Frontiers in Immunology, 2020, 11, 602802.	4.8	7
46	The BiTE (bispecific Tâ€cell engager) platform: Development and future potential of a targeted immunoâ€oncology therapy across tumor types. Cancer, 2020, 126, 3192-3201.	4.1	116
47	Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2020, 19, 1875-1888.	4.1	34
48	Tollâ€like receptor 7/8â€matured RNAâ€transduced dendritic cells as postâ€remission therapy in acute myeloid leukaemia: results of a phase I trial. Clinical and Translational Immunology, 2020, 9, e1117.	3.8	23
49	Ten things the hematologist wants you to know about CAR-T cells. Intensive Care Medicine, 2020, 46, 1243-1245.	8.2	5
50	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunology, Immunotherapy, 2020, 69, 1353-1362.	4.2	34
51	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia, 2020, 34, 3161-3172.	7.2	141
52	Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells. Blood, 2020, 136, 33-34.	1.4	11
53	Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies. Blood, 2020, 136, 41-42.	1.4	1
54	Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity. Blood, 2020, 136, 34-35.	1.4	3

#	Article	IF	Citations
55	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. European Radiology Experimental, 2020, 4, 63.	3.4	38
56	Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).. Journal of Clinical Oncology, 2020, 38, 7508-7508.	1.6	70
57	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development. JMIR Public Health and Surveillance, 2020, 6, e19033.	2.6	46
58	Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML.. Journal of Clinical Oncology, 2020, 38, 7536-7536.	1.6	2
59	Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up. Blood, 2020, 136, 35-35.	1.4	1
60	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. Blood, 2020, 136, 10-11.	1.4	0
61	Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). Blood, 2020, 136, 39-40.	1.4	6
62	Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTEÂ® Construct Stimulation in Vitro. Blood, 2020, 136, 44-45.	1.4	1
63	Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia, 2019, 33, 64-74.	7.2	212
64	Advances in cancer immunotherapy 2019 â€“ latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	8.6	401
65	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. Journal of Clinical Medicine, 2019, 8, 579.	2.4	48
66	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. Transfusion Medicine and Hemotherapy, 2019, 46, 15-24.	1.6	107
67	Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction. Haematologica, 2019, 104, e510-e513.	3.5	3
68	Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis. Blood Advances, 2019, 3, 2696-2699.	5.2	8
69	Abundant glutamic acid decarboxylase (GAD)â€reactive B cells in gadâ€antibodyâ€“associated neurological disorders. Annals of Neurology, 2019, 85, 448-454.	5.3	18
70	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTEÂ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood, 2019, 134, 833-833.	1.4	55
71	Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTEÂ®-Mediated Cytotoxicity in Vitro. Blood, 2019, 134, 2632-2632.	1.4	3
72	Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia, 2018, 32, 1598-1608.	7.2	106

#	Article	IF	Citations
73	A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica, 2018, 103, 456-465.	3.5	84
74	Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia, 2018, 32, 313-322.	7.2	61
75	End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry. Transplantation, 2018, 102, 868-875.	1.0	26
76	Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemiaâ€"a phase 3 study. Leukemia, 2018, 32, 2558-2571.	7.2	20
77	Bifunctional PD-1 Ã— Î±CD3 Ã— Î±CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood, 2018, 132, 2484-2494.	1.4	73
78	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Transplantation, 2018, 102, 1914-1923.	1.0	11
79	Cytokine release syndrome. , 2018, 6, 56.		1,055
80	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. OncoImmunology, 2018, 7, e1472195.	4.6	21
81	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. Frontiers in Immunology, 2018, 9, 385.	4.8	144
82	Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica, 2018, 103, 1853-1861.	3.5	96
83	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	1.6	168
84	A fluorescence in situ hybridizationâ€based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia. Genes Chromosomes and Cancer, 2017, 56, 632-638.	2.8	0
85	The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3. Cell, 2017, 171, 1110-1124.e18.	28.9	431
86	Diagnosis of <scp>CLL</scp> revisited: increased specificity by a modified fiveâ€marker scoring system including <scp>CD</scp>200. British Journal of Haematology, 2017, 179, 480-487.	2.5	49
87	SIRPÎ±-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget, 2017, 8, 11284-11301.	1.8	17
88	Recent developments in immunotherapy of acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 142.	17.0	118
89	Targeting CD157 in AML using a novel, Fc-engineered antibody construct. Oncotarget, 2017, 8, 35707-35717.	1.8	27
90	Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. OncoImmunology, 2016, 5, e1178421.	4.6	15

#	Article	IF	Citations
91	Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood, 2016, 128, 686-698.	1.4	456
92	Features of Human CD3+CD20+ T Cells. Journal of Immunology, 2016, 197, 1111-1117.	0.8	144
93	Future outlook for acute leukemias. , 2016, , 77-92.		0
94	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica, 2016, 101, 932-940.	3.5	50
95	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia, 2016, 30, 484-491.	7.2	201
96	PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia. Blood, 2016, 128, 1209-1209.	1.4	1
97	Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade. Blood, 2016, 128, 764-764.	1.4	10
98	An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. PLoS ONE, 2015, 10, e0120925.	2.5	78
99	Immunotherapy in Tumors. Deutsches Ärzteblatt International, 2015, 112, 809-15.	0.9	31
100	Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. Journal of Hematology and Oncology, 2015, 8, 111.	17.0	131
101	T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. Journal of Hematology and Oncology, 2015, 8, 93.	17.0	127
102	Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia, 2015, 29, 377-386.	7.2	58
103	Clinical overview of anti-CD19 BiTEÂ® and ex vivo data from anti-CD33 BiTEÂ® as examples for retargeting T cells in hematologic malignancies. Molecular Immunology, 2015, 67, 58-66.	2.2	40
104	Immunotherapy for Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 207-214.	3.4	44
105	Bendamustine and the immune system: a wolf in sheep's clothing?. Leukemia and Lymphoma, 2015, 56, 837-838.	1.3	2
106	RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML. Cancer Immunology, Immunotherapy, 2015, 64, 1505-1515.	4.2	3
107	Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia, 2015, 29, 828-838.	7.2	63
108	Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. Blood, 2015, 126, 816-816.	1.4	5

#	Article	IF	Citations
109	Identifying Immune Resistance Mechanisms to CD33/CD3 BiTEÂ® Antibody Construct (AMG 330) Mediated Cytotoxicity. Blood, 2015, 126, 3677-3677.	1.4	0
110	Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica, 2014, 99, 1317-1325.	3.5	71
111	Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity. Bone Marrow Research, 2014, 2014, 1-9.	1.7	0
112	New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2014, 63, 1093-1103.	4.2	38
113	Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities. ACS Chemical Biology, 2014, 9, 802-811.	3.4	38
114	Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leukemia Research, 2014, 38, 964-969.	0.8	34
115	CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cellâ€“engaging antibody AMG 330. Blood, 2014, 123, 356-365.	1.4	168
116	Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia. PLoS ONE, 2014, 9, e89560.	2.5	60
117	Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy, 2013, 5, 63-78.	2.0	20
118	Structures of the human and Drosophila 80S ribosome. Nature, 2013, 497, 80-85.	27.8	474
119	Proposal For a Novel Scoring System For The Diagnosis Of CLL. Blood, 2013, 122, 4150-4150.	1.4	3
120	High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008). Blood, 2013, 122, 619-619.	1.4	4
121	CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells. PLoS ONE, 2012, 7, e44266.	2.5	54
122	Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Annals of Hematology, 2012, 91, 1051-1063.	1.8	26
123	Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma. Leukemia Research, 2012, 36, 799-801.	0.8	2
124	Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. Journal of Translational Medicine, 2011, 9, 151.	4.4	36
125	A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leukemia and Lymphoma, 2010, 51, 447-455.	1.3	29
126	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 433-436.	17.8	39

#	Article	IF	Citations
127	Epsteinâ€“Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. International Journal of Hematology, 2008, 88, 434-440.	1.6	19
128	Generation of EBV-specific T Cells for Adoptive Immunotherapy: A Novel Protocol Using Formalin-fixed Stimulator Cells to Increase Biosafety. Journal of Immunotherapy, 2007, 30, 817-824.	2.4	13
129	Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transplant Immunology, 2007, 17, 203-210.	1.2	84
130	Dendritic Cell Maturation Stage Determines Susceptibility to the Proteasome Inhibitor Bortezomib. Human Immunology, 2007, 68, 147-155.	2.4	46
131	Radiologic and Pathologic Features of a Posttransplantation Primary Central Nervous System Lymphoma Demonstrating Epstein-Barr Virusâ€“Positive Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 535-537.	1.4	4
132	Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. Transplantation, 2006, 82, 1093-1100.	1.0	48
133	Impairment of Circulating Myeloid Dendritic Cells in Immunosuppressed Renal/Pancreas Transplant Recipients. Transplantation, 2006, 82, 779-787.	1.0	8
134	Epsteinâ€“Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Annals of Hematology, 2006, 85, 478-484.	1.8	48
135	A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.. Blood, 2006, 108, 2721-2721.	1.4	5
136	Dendritic Cells Expand Epstein Barr Virus Specific CD8+ T Cell Responses More Efficiently Than EBV Transformed B Cells. Human Immunology, 2005, 66, 938-949.	2.4	21
137	Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient. Leukemia, 2004, 18, 2050-2053.	7.2	13
138	Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.. Blood, 2004, 104, 2640-2640.	1.4	14
139	Dendritic Cells for the Induction of EBV Immunity. Recent Results in Cancer Research, 2002, 159, 38-43.	1.8	3
140	Dendritic Cells Cross-Present Latency Gene Products from Epstein-Barr Virusâ€“Transformed B Cells and Expand Tumor-Reactive Cd8+ Killer T Cells. Journal of Experimental Medicine, 2001, 193, 405-412.	8.5	104
141	Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1. Journal of Experimental Medicine, 2000, 191, 1649-1660.	8.5	323
142	Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus. Blood, 1999, 94, 1372-1381.	1.4	63
143	Presentation of Epstein-Barr virus latency antigens to CD8+, interferon-Î³-secreting, T lymphocytes. European Journal of Immunology, 1999, 29, 3995-4001.	2.9	42
144	Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus. Blood, 1999, 94, 1372-1381.	1.4	18

#	Article	IF	Citations
145	Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. Blood, 1999, 94, 1372-81.	1.4	15
146	Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. Journal of Immunology, 1999, 163, 6762-8.	0.8	287
147	Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells. Journal of Experimental Medicine, 1998, 188, 2163-2173.	8.5	583
148	A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells. Blood, 1997, 90, 3640-3646.	1.4	222
149	Expression of Surface Markers on Alveolar Macrophages From Symptomatic Patients with HIV Infection as Detected by Flow Cytometry. Chest, 1994, 105, 1324-1334.	0.8	45
150	Akute Myeloische LeukÃmie: Eigene T-Zellen als Waffe gegen LeukÃmie einsetzen. , 0, , .		0
151	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	3